For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.co.jp/
Daiichi Sankyo to Transfer All Shares of Saitama Daiichi Pharmaceutical
Tokyo, April 23, 2007-Daiichi Sankyo Co., Ltd. (Hereafter Daiichi Sankyo) and Nipro Corporation(President: Minoru Sano; Hereafter Nipro) have agreed to transfer all shares of Saitama Daiichi PharmaceuticalCo., Ltd. (President: Koshiro Nakamura; Hereafter Saitama Daiichi), a fully owned subsidiary of Daiichi Sankyo,to Nipro.
Saitama Daiichi is mainly engaged in businesses of Research, Development, manufacturing, exporting and importing of Prescription and Over-the-counter drugs of transdermal medicines, ointments and liquid preparations. Saitama Daiichi is especially highly known for its technology in the field of transdermal medicine.
After Nipro acquires all shares of Saitama Daiichi which Daiichi Sankyo owns, Saitama Daiichi will operate its business as a 100% subsidiary of Nipro. Nipro is involved in the development of DDS (Drug Delivery Systems) carriers and new drug administration systems, and has high interest in the field of Transdermal Therapeutic Systems (TTS) to expand the company's contract manufacturing capabilities. Attaining Saitama Daiichi's technologies in transdermal medicine and manufacturing capabilities will allow Nipro to engage in operations in broader fields of contract manufacturing, in addition to its current business in oral and injection drugs. Nipro also expects not only to gain new businesses in research development and contract manufacturing from Nipro Group's customer network, but also to have Saitama Daiichi function as the main role in developing and manufacturing new products for sale by Nipro.
If Daiichi Sankyo's business performance of the fiscal year ended March 2008 is changed due to this share transfer, we will disclose it at a later date.
| |
| 1. |
Dates of Share Transfer |
| |
Signing of Share Purchase Agreement |
April 23,2007 |
| |
Share Transfer |
May 15, 2007(Planned) |
| |
|
|
|
| 2. |
Outline of the Companies Involved |
| |
(1) |
Saitama Daiichi Pharmaceutical Co., Ltd. |
| |
|
Location of Head Office: |
8-1 Minamisakaecho-cho, Kasukabe-shi, Saitama |
| |
|
Date Established: |
February 15, 1963 |
| |
|
Representative: |
Koshiro Nakamura |
| |
|
Capital: |
1,005 million yen |
| |
|
Sales: |
7,315 million yen（Fiscal year ended March 2006） |
| |
|
Number of Employees: |
301（as of January 31, 2007） |
| |
|
Major Businesses: |
Research, development, manufacturing, marketing, importing and exporting of pharmaceutical products in areas of transdermal drugs |
| |
|
|
|
| |
(2) |
Nipro Corporation |
|
| |
|
Location of Head Office: |
3-9-3 Honjo-Nishi, Kita-ku, Osaka |
| |
|
Date Established: |
July 8, 1954 |
| |
|
Representative: |
Minoru Sano |
| |
|
Capital: |
28,663 million yen |
| |
|
Sales: |
206,801 million yen（Fiscal year ended March 2006 consolidated） |
| |
|
Number of Employees: |
9,048（as of March 31, 2006 consolidated） |
| |
|
Major Businesses: |
Manufacture and sales of various glass products,medical supplies and devices, and pharmaceuticals |
| |
|
|
|
End